Off-Label Prescribing in a Longevity Clinic: Rules in 2026

Off-label prescribing in a longevity clinic is generally permitted when an independently licensed clinician determines that an FDA-approved drug is medically appropriate for an individual patient. FDA approval of metformin does not include aging or lifespan extension, and a clinic cannot turn research such as TAME into a promise of longevity benefit. Marketing must remain truthful, nonmisleading, and supported by competent and reliable scientific evidence.

What does off-label prescribing mean for a longevity clinic?

Off-label prescribing means using an approved drug for a disease, condition, or use that is not included in its FDA-approved labeling. FDA generally allows healthcare providers to make that decision when they judge the use medically appropriate for a particular patient. FDA has not, however, determined that the drug is safe and effective for that unapproved use.

For a business owner, four categories should remain separate:

1. 1FDA-approved indication: The use and labeling FDA has reviewed for the drug.
2. 2Clinician-selected off-label use: A licensed clinician’s individualized decision outside that labeling.
3. 3Investigational use: Research conducted under a study protocol, such as a clinical trial.
4. 4Commercial communication: Website, advertising, social media, testimonial, and sales language about the service.

A protocol, intake form, algorithm, subscription, or medical-director relationship does not eliminate the need for patient-specific clinical judgment. The owner can design the business and administrative workflow; the treating clinician decides whether prescribing is appropriate.

That distinction also matters when evaluating what a white-label longevity program includes. Technology can support intake, documentation, communication, and operations without becoming the prescriber.

Can a longevity clinic prescribe metformin off label?

A longevity clinic may generally offer a clinician review of metformin for an off-label purpose, but the clinician—not the clinic owner or software—must decide whether prescribing is appropriate for the individual patient. Metformin is FDA-approved for certain metabolic conditions; FDA has not approved it to treat aging, anti-aging, lifespan extension, or general longevity.

The clinic should avoid presenting an off-label service as though it were an FDA-approved longevity treatment. A compliant commercial description can distinguish the approved status from the research question:

That language is educational rather than a promise of a clinical outcome. It also avoids telling a particular clinician what to prescribe or telling a patient what to take.

What does the TAME trial actually show?

The Targeting Aging with Metformin, or TAME, study was designed as a multicenter, placebo-controlled study of approximately 3,000 older adults with a composite outcome involving multiple age-related diseases. Its proposed purpose was to test whether metformin could delay age-related disease—not to establish that metformin already extends human lifespan.

The verified record reviewed for AGE-M, NCT06459310, describes a Phase II exploratory study involving approximately 130 middle-aged and older men. The record lists an estimated start date of June 30, 2024, estimated primary completion of September 30, 2026, and estimated study completion of July 31, 2028. It is listed as recruiting and does not report results.

A longevity clinic may accurately describe TAME as a research program or study design. It should not say that TAME proved metformin extends life, prevents dementia, prevents cancer, or prevents cardiovascular disease. The research rationale is not the same as a completed treatment result.

TAME and AGE-M: a business-use distinction

What may a longevity clinic say about off-label medications?

A clinic may explain the drug’s FDA-approved status, identify the proposed research question, state that a use is off-label, and explain that an independent clinician makes the prescribing decision. The claim must still be accurate in context, including the population, formulation, endpoint, and limits of the cited evidence.

The FTC’s health-products guidance requires health advertising to be truthful, not misleading, and supported by competent and reliable scientific evidence. A study must support the specific claim the advertisement communicates. A testimonial does not replace that evidence; it may also communicate an implied efficacy claim.

What a clinic may and may not say

This is not merely a copywriting issue. A headline, testimonial, social post, affiliate statement, or before-and-after presentation can communicate a health claim even when the page includes a disclaimer elsewhere.

Who decides whether to prescribe off label?

The clinician responsible for the patient’s care makes the prescribing decision. A clinic can credential clinicians, establish documentation standards, require chart review, and maintain a medical director. It should not use the medical director as a blanket approver or pressure clinicians to follow a predetermined prescription outcome.

MDLaunchr provides infrastructure for branded telehealth businesses, while independently licensed clinicians retain clinical decision-making authority. That division should be reflected in contracts, staff training, workflows, patient communications, and website language.

A founder should have the clinical workflow reviewed by the responsible clinician and the business structure and advertising approach reviewed by qualified counsel or the applicable state board before launch. This article is educational, not legal or medical advice.

What are the off-label prescribing telehealth rules?

Telehealth rules are state-dependent. The relevant requirements may turn on where the patient is located, the clinician’s license, the professional’s scope of practice, the encounter format, the medication, supervision, and the business entity. The following states illustrate why a national workflow cannot rely on one uniform rule.

California: examination and medical indication matter

The Medical Board of California states that dangerous drugs generally require an appropriate prior examination and a medical indication. California Business and Professions Code sections 2242 and 2242.1 address prescribing, dispensing, or furnishing dangerous drugs over the internet without an appropriate prior examination and medical indication. The Board also states that clinicians treating patients located in California must be California-licensed and held to the same standard of care as in-person practice.

For a California workflow, a bare intake form or automatic prescription approval is not a sound substitute for the required clinical evaluation. The business should support documentation of the evaluation, indication, informed consent, clinical reasoning, and clinician licensure.

Florida: questionnaire-only prescribing is not enough

Florida’s telemedicine prescribing rule states that prescribing based solely on an electronic medical questionnaire constitutes substandard practice. The rule calls for a documented patient evaluation, including history and physical examination sufficient to establish the diagnosis for which a legend drug is prescribed, discussion of treatment options and risks and benefits, and contemporaneous medical records.

Florida materials also state that a telehealth provider may conduct an evaluation sufficient to diagnose and treat a patient without necessarily performing a physical examination before using telehealth, depending on the circumstances and applicable standard of care. The operational point is narrower: telehealth can be available, but an automated questionnaire alone cannot replace the required evaluation.

Texas: delegation requires a formal framework

The Texas Medical Board states that physicians delegating prescriptive authority to physician assistants or advanced practice nurses must comply with Texas Occupations Code requirements, including registration and a prescriptive authority agreement. The Board also recognizes real-time audio or visual communication as direct patient care for certain regulatory purposes.

A Texas clinic using PAs or APNs should verify scope of practice, delegation, registration, prescriptive authority agreements, and chart-supervision processes. A “medical director” label alone does not establish that framework.

New York: entity structure can be a launch issue

New York Department of Health materials describe physician-owned professional practice structures and state that corporate-practice restrictions generally prevent an unauthorized corporation or unlicensed entity from providing or arranging professional services. A non-physician longevity company should obtain state-specific advice on professional entities, management services, branding, compensation, contracting, and clinical control.

These examples are not national rules. A clinic’s location, patient location, clinician license, entity structure, and service design all need to be evaluated together.

How should a clinic operationalize off-label prescribing?

A useful launch sequence separates clinical governance from marketing production:

1. 1Define the service: Identify whether the offering is education, clinical evaluation, prescribing, research participation, or a combination.
2. 2Map approved and off-label uses: Maintain a formulary record that identifies FDA-approved indications and clearly labels any clinician-selected off-label use.
3. 3Build the evaluation workflow: Capture patient location, clinician licensure, history, examination or telehealth evaluation requirements, informed consent, alternatives, risks, follow-up, and clinical reasoning as applicable.
4. 4Preserve clinical independence: Prevent owners, sales staff, marketers, and software from selecting patients for automatic approval or directing a prescription outcome.
5. 5Create a claims file: For every public claim, retain the source, study population, endpoint, limitations, date reviewed, and exact copy supported by the evidence.
6. 6Review every channel: Check website pages, paid ads, social media, testimonials, affiliates, influencers, emails, and sales scripts rather than reviewing only the main landing page.
7. 7Apply state controls: Configure licensure, consent, documentation, supervision, delegation, and entity requirements by patient location.
8. 8Audit after launch: Recheck claims and state requirements when evidence, agency guidance, trial status, or business operations change.

The broader telehealth business models for clinics can help frame the administrative side, but revenue structure does not change who controls medical judgment.

What should a longevity clinic owner check before launch?

Use this checklist before publishing an off-label longevity page or opening enrollment:

• Does the page state that FDA has not approved any medication to treat aging?
• Does it distinguish FDA-approved indications from off-label use?
• Does it describe TAME and AGE-M accurately, without claiming completed proof of longevity benefit?
• Does it avoid dosing, titration, administration, patient-specific prescribing instructions, and outcome promises?
• Does the responsible clinician control evaluation and prescribing decisions?
• Does the workflow prevent questionnaire-only or automatic approval where state requirements call for more?
• Are California, Florida, Texas, New York, and other target states reviewed separately rather than treated as one national rule?
• Are testimonials, affiliates, and social posts included in the advertising review?
• Is the evidence file specific to each claim, population, product, outcome, and context?
• Are clinical and administrative roles clear in contracts and patient-facing materials?

For founders evaluating infrastructure rather than writing the clinical policy themselves, the programs hub provides the relevant starting point. To see how a branded longevity operation can be structured, see the white-label longevity program.